What question did this study set out to answer?

This review focuses on addressing the unmet need for relapse prevention in acute myeloid leukemia (AML) through maintenance therapies.

June 21, 2026Current OncologyOpen Access

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions

View Full Paper

Ask AI

Bookmark

This review focuses on addressing the unmet need for relapse prevention in acute myeloid leukemia (AML) through maintenance therapies.
Examined current evidence from randomized and phase II/III trials
Evaluated hypomethylating agents, FLT3 inhibitors, and immunotherapeutic strategies
Emphasized measurable residual disease (MRD)-guided approaches in post-remission settings
Oral azacitidine (CC-486) improved overall survival in older AML patients not eligible for transplant.
Post-transplant maintenance with sorafenib and gilteritinib in FLT3-mutated AML significantly reduces relapse risk.
Emerging evidence supports MRD as a predictive biomarker for treatment benefit in maintenance therapy.

No takes yet. Share an insight, caveat, or question.

Review examines maintenance strategies in AML management, highlighting new therapies and biomarkers for relapse prevention.

Velarde et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark